Drug intelligence / Profile preview

Glutarex

Development stage: Unknown
Lead developer: Abbott
Administration: Oral

Overview

Glutarex is a **medical food** developed by Abbott Nutrition for the dietary management of **glutaric aciduria type I**. It is a lysine-free and tryptophan-free amino acid-modified oral powder designed to provide protein nutrition while minimizing the precursor amino acids that patients with glutaric aciduria type I cannot properly metabolize. The formulation includes essential and non-essential amino acids and added **L-carnitine** to support excretion of toxic metabolites. Glutarex is intended for use under medical supervision, with prescribed supplemental intact protein and fluids, and functions through metabolic and nutritional support rather than a conventional pharmacologic target-based mechanism.

Brand names: Glutarex
Other names: Glutarex-2Glutarex2Glutarex 2

Beyond the preview

Go deeper on Glutarex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutarex.

Explore the full profile